Cord blood antibody following maternal SARS-CoV-2 inactive vaccine (CoronaVac) administration during the pregnancy임신 중 산모의 SARS-CoV-2 불활성 백신(CoronaVac) 투여 후 제대혈 항체Article Published on 2021-10-032022-09-11 Journal: Human vaccines & immunotherapeutics [Category] SARS, 치료기술, [키워드] administration adverse event adverse events age anti-RBD anti-receptor-binding domain antibodies antibody arbitrary unit Beijing Birth Birth weight Blood Care China Cord blood CoronaVac detectable Efficacy first dose first identified case gestation gestational age HCW Health Health care healthy IgG antibodies inactivated inactive life Maternal mother Newborn placental Pregnancy RBD reported SARS-CoV-2 SARS-CoV-2 IgG SARS-CoV-2 IgG antibodies SARS-CoV-2 IgG antibody SARS-COV-2 infection SARS-CoV-2 spike protein SARS-CoV-2 vaccine SARS-CoV-2 vaccines Science second dose sera Sinovac Spike protein the vaccine transfer vaccination Vaccine virus [DOI] 10.1080/21645515.2021.1947099 PMC 바로가기 [Article Type] Article
Acute relapse and poor immunization following COVID-19 vaccination in a rituximab-treated multiple sclerosis patient리툭시맙 치료 다발성 경화증 환자에서 COVID-19 백신 접종 후 급성 재발 및 불량한 면역Case Reports Published on 2021-10-032022-09-11 Journal: Human vaccines & immunotherapeutics [Category] MERS, SARS, 진단, 치료기술, [키워드] Adenovirus adenovirus-based adhere adverse event anti-CD20 anti-SARS-CoV-2 anti-SARS-CoV-2 antibodies anti-SARS-CoV-2 antibody assessments Ataxia Autoimmune disease Autoimmune diseases Awareness cerebellar peduncle clinical trial clinician Corticosteroid corticosteroid therapy COVID-19 COVID-19 vaccination COVID-19 vaccine COVID-19 vaccines decision Detection limit develop diagnosed dose Efficacy fatigue first dose FIVE Gam-COVID-Vac Immunity immunization lesions magnetic resonance imaging Mild symptom mild symptoms monoclonal antibody multiple sclerosis myalgia Neurological deficit neurological deficits oral steroid Patient Phase I raise receive receiving right hemiplegia risk rituximab SARS-CoV-2 steroid subpopulations the patient the vaccine treated Treatment vaccination schedule Vaccine Vaccines weakness [DOI] 10.1080/21645515.2021.1928463 PMC 바로가기 [Article Type] Case Reports
Antibody Persistence 6 Months Post-Vaccination with BNT162b2 among Health Care WorkersBrief Report Published on 2021-10-032022-10-28 Journal: Vaccines [Category] COVID-19, [키워드] age analyzed antibody Antibody Response Antigen asked baseline BMI BNT162b2 carried chemiluminescent immunoassay collected Comorbidity correlation COVID-19 COVID-19 negative COVID-19 pandemic decrease demonstrated dose first dose Gender geometric mean concentration greater HCW Health care worker highest IgG antibody immune response immunogenicity data median men Month mRNA vaccine National of BNT162b2 other variable participant persistence positive positive individual reached S1/S2 SARS-CoV-2 SARS-COV-2 infection second vaccination sera serum sample significant increase supported the vaccine turn Vaccine was performed women worker [DOI] 10.3390/vaccines9101125 PMC 바로가기 [Article Type] Brief Report
Disease activity and humoral response in patients with inflammatory rheumatic diseases after two doses of the Pfizer mRNA vaccine against SARS-CoV-2SARS-CoV-2에 대한 Pfizer mRNA 백신 2회 접종 후 염증성 류마티스 질환 환자의 질병 활성 및 체액 반응Article Published on 2021-10-012022-09-11 Journal: Annals of the rheumatic diseases [Category] MERS, SARS, 임상, 진단, 치료기술, [키워드] (Abbott Abbott administration age antirheumatic agents Autoimmune Autoimmune diseases biological therapy blood sample Blood samples consecutive patients COVID-19 disease dose humoral Humoral response IgG IgG antibodies IgG antibody immunomodulating drug immunomodulating drugs immunomodulatory therapy Inflammatory majority Messenger RNA mounted mRNA mRNA vaccine Patient patients patients treated Pfizer receiving recruited remained reported rheumatic disease Rheumatic diseases rheumatology SARS-CoV-2 SARS-CoV-2 virus second dose second dose of vaccine second vaccination serology Side effect the SARS-CoV-2 the vaccine treated Trial vaccination Vaccine [DOI] 10.1136/annrheumdis-2021-220503 PMC 바로가기 [Article Type] Article
A pragmatic outreach pilot to understand and overcome barriers to COVID-19 vaccination in abdominal organ transplantArticle Published on 2021-10-012022-10-05 Journal: Transplant infectious disease : an official journa [Category] SARS, 임상, [키워드] abdominal organ acute respiratory syndrome adverse outcome age antibody Black race common conducted coronavirus disease COVID-19 COVID-19 vaccination COVID-19 vaccine decrease Efficacy effort Health Health disparities Health messaging higher risk immune response increased risk individual initial kidney transplant recipient lack liver outreach overcome Patient Pragmatic pragmatic study Public question recipient recipients recommendations reported resources SARS-CoV-2 Side effects Society solid organ solid organ transplant the vaccine Transplant transplantation Trial vaccination vaccination rate Vaccine virus white [DOI] 10.1111/tid.13722 PMC 바로가기 [Article Type] Article
Exploring the therapeutic potential of marine-derived bioactive compounds against COVID-19COVID-19에 대한 해양 유래 생리 활성 화합물의 치료 가능성 탐색Review Published on 2021-10-012022-09-11 Journal: Environmental science and pollution research inter [Category] SARS, 치료제, [키워드] anti-inflammatory properties antioxidant Antiviral antiviral properties antiviral property bioactive compounds Compound condition COVID-19 develop Drug development effective Halobiont immunomodulatory Marine-derived mode No effective drug ocean organism Organisms pharmacological Repurposed drug Repurposed drugs Sponge Symptom The therapeutic potential. the vaccine therapeutic potential these compounds Transmission virus [DOI] 10.1007/s11356-021-16104-6 PMC 바로가기 [Article Type] Review
Introduction of the BNT162b2 vaccine during a COVID-19 nursing home outbreak코로나19 요양원 발생 시 BNT162b2 백신 도입Article Published on 2021-10-012022-09-11 Journal: American journal of infection control [Category] SARS, 치료기술, [키워드] accounted Active surveillance Affair Analysis Antigen Asymptomatic COVID-19 attack rate BNT162b2 BNT162b2 vaccine center CLC coronavirus disease Coronavirus disease 2019 COVID-19 COVID-19 outbreak detect Efficacy first and second dose immunization Infection prevention median age mRNA vaccine nursing home nursing homes occur occurred of BNT162b2 outbreak reduce resident SARS-CoV-2 second dose single dose Single-dose surveillance testing the vaccine Transmission twice weekly Twice weekly SARS-CoV-2 tests vaccination Vaccine Vaccine analysis vaccine dose veteran Viral load was determined was used [DOI] 10.1016/j.ajic.2021.07.019 PMC 바로가기 [Article Type] Article
A patient presenting with ARDS after COVID-19 vaccination: A COVID-19 case reportCOVID-19 예방접종 후 ARDS로 내원한 환자: COVID-19 사례 보고Case Reports Published on 2021-10-012022-09-11 Journal: Journal of infection and public health [Category] SARS, 치료기술, [키워드] acute respiratory distress syndrome ARDS ARDS (Acute Respiratory Distress Syndrome) caused Clinical finding Clinical findings clinical picture COVID-19 COVID-19 case COVID-19 cases COVID-19 PCR test disease ICU ICU admission IgG immunization intensive care male occur pandemic Patient PCR test presenting preventive measure respiratory respiratory distress Respiratory distress syndrome SARS-CoV SARS-CoV IgG/M. SARS-CoV-2 second dose severe acute respiratory syndrome Coronavirus severe acute respiratory syndrome coronavirus-2 Stress test result the patient the vaccine vaccinated individuals Vaccine [DOI] 10.1016/j.jiph.2021.05.017 PMC 바로가기 [Article Type] Case Reports
Early clinical trial data and real-world assessment of COVID-19 vaccines: Insights from the Society of Infectious Diseases PharmacistsCOVID-19 백신의 초기 임상 시험 데이터 및 실제 평가: 전염병 약사 협회의 통찰력Review Published on 2021-10-012022-09-11 Journal: Pharmacotherapy [Category] SARS, 변종, 임상, [키워드] Ad26.COV2.S authorization benefit BNT162b2 can be used clinical experience clinical trial clinical trials Community Coronavirus 2019 COVID-19 COVID-19 vaccine COVID-19 vaccines develop effective Effectiveness Emergency Emergency use authorization EUA Immunity Inc. Infectious disease initial insight LLC Moderna mRNA mRNA-1273 of BNT162b2 Pfizer Pharmacist Population SARS-CoV-2 SARS-CoV-2 variant SARS-CoV-2 variants Society the United State the vaccine United States vaccination Vaccines [DOI] 10.1002/phar.2622 PMC 바로가기 [Article Type] Review
Immunoglobulin G antibody response to the Sputnik V vaccine: previous SARS-CoV-2 seropositive individuals may need just one vaccine dose스푸트니크 V 백신에 대한 면역글로불린 G 항체 반응: 이전에 SARS-CoV-2 혈청 양성 반응을 보인 개인은 단 한 번의 백신 접종이 필요할 수 있습니다.Article Published on 2021-10-012022-09-11 Journal: International Journal of Infectious Diseases [Category] MERS, SARS, 진단, 치료법, [키워드] antibody antibody levels Antibody Response antibody response against Antibody responses booster dose Cohort develop domain dose doses enzyme enzyme-linked immunosorbent enzyme-linked immunosorbent assay evaluated had no IgG IgG antibodies IgG antibody IgG immune response IgG response Immunoglobulin Immunoglobulin G individual individuals nucleocapsid protein nucleocapsid protein (NP) RBD receiving Receptor-binding domain Receptor-binding domain (RBD) S/P S/P ratio SARS-CoV-2 SARS-CoV-2 antigen SARS-CoV-2 antigens second dose seronegative seropositive seropositive individual seropositive subject seropositive subjects significant increase Spike protein Sputnik V vaccine the receptor-binding domain the spike protein the vaccine triggered vaccination Vaccine vaccine booster dose. vaccine dose Venezuela [DOI] 10.1016/j.ijid.2021.07.070 PMC 바로가기 [Article Type] Article